2 results match your criteria: "Gromo Institute and Sinus Center[Affiliation]"
Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?
Clin Rev Allergy Immunol
October 2020
Department of Otolaryngology, Jacobs School of Medicine and Biomedical Sciences, Gromo Institute and Sinus Center, University at Buffalo, The State University of New York, 1237 Delaware Avenue, Buffalo, NY, 14209, USA.
This review article aims to outline what is known in the pathophysiology of chronic rhinosinusitis with nasal polyposis (CRSwNP) and describe the mechanism of the biologic agents being investigated for this disease. Chronic rhinosinusitis with nasal polyposis is an inflammatory disease of the nasal and paranasal mucosa, which causes symptoms of nasal obstruction, hyposmia, and rhinorrhea. Conventional therapy for CRSwNP includes intranasal corticosteroids (INCS) and polypectomy, but INCS offer only modest benefits, and recurrence after surgery is common.
View Article and Find Full Text PDFCorrelation of Symptoms, Clinical Signs, and Biomarkers of Inflammation in Postsurgical Chronic Rhinosinusitis.
Ann Otol Rhinol Laryngol
June 2017
1 Department of Otorhinolaryngology, University at Buffalo School of Medicine and Biomedical Sciences, The State University of New York, Gromo Institute and Sinus Center, Buffalo, New York, USA.
Objective: The study aimed to evaluate symptoms described by patients with chronic rhinosinusitis with polypoid changes/nasal polyps and their correlation with computed tomography (CT), nasal endoscopy, and intranasal biomarkers.
Study Design: Prospective multicenter study symptom data from postsurgical adult chronic rhinosinusitis study participants with recurrent disease refractory to medical therapy were analyzed in comparison with objective data.
Methods: Using logistic regression analysis, participant-rated 16-question surveys from 258 participants were assessed for correlation with nasal endoscopy scores, CT percentage of sinus occlusion, and intranasal biomarkers of fungal antigens (Alternaria and Aspergillus), eosinophilic inflammation (eosinophil-derived neurotoxin [EDN] and major basic protein [MBP]), and inflammatory cytokines (interleukins 5 and 13).